GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Evonile Pharma Ltd

Evonile Pharma Submits Letter of Offer for Rights Issue of Rs. 8,847.54 Million

FUNDRAISE ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 05 Nov 2026, 08:20 PM IST  ·  BSE ID: 03b3b7bb-e4d7-4184-a307-3efbb9aa3136
View Original BSE Filing (PDF)
💡
In Simple Terms
The company is asking existing shareholders to buy new shares to raise money.
🤖 AI Summary
  • Evonile Pharma files Letter of Offer for rights issue of up to Rs. 8,847.54 million.
  • Issue comprises 10,287,832 partly paid-up equity shares at Rs. 860 per share.
  • Rights offered in ratio of 5 shares for every 12 held by eligible shareholders.
  • Record date for determining eligibility is November 11, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Rights Issue Size
up to ₹8,847.54 million
Number of Partly Paid-up Equity Shares
10,287,832
Issue Price per Share
₹860.00
Premium per Share
₹855.00
Ratio of Rights Equity Shares to Existing Equity Shares
5 for every 12
Record Date
November 11, 2026
🏢 How This Affects the Company
💰
Financial Impact
The rights issue aims to raise Rs. 8,847.54 million, which will bolster the company's capital base. The issue price of Rs. 860 per share, including a premium of Rs. 855, indicates a significant valuation expectation.
⚠️
Risk Impact
The success of the rights issue depends on shareholder subscription. Failure to fully subscribe could impact the company's capital raising plans.
👥 What This Means For Shareholders
✅
Action Required
Eligible equity shareholders should review the Letter of Offer for details on subscription and payment terms.
👤
Who Is Affected
Eligible equity shareholders as on the record date of November 11, 2026, are entitled to subscribe to the rights equity shares in the ratio of 5:12.
🔍
Management Signal
Management is proceeding with a significant capital raise through a rights issue, signaling a need for funds for corporate purposes.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Confirmation of Rights Issue opening and closing dates.
Shareholder response and subscription levels for the rights issue.
Allotment status of the rights equity shares post-issue closure.
MEDIUM RISK Capital raising through rights issue carries market execution risk and depends on shareholder participation.
💡 Investor Takeaway
Evonile Pharma submitted its Letter of Offer for a rights issue up to Rs. 8,847.54 million, offering 10,287,832 partly paid-up equity shares at Rs. 860 each, with a record date of November 11, 2026.
⚖️ Strengths & Concerns

✅ Positives

  • Rights issue size of Rs. 8,847.54 million to fund company operations and growth.
  • Issue price of Rs. 860 per share includes a substantial premium of Rs. 855.
📅 Company Track Record
Evonile Pharma Limited, formerly known as Novartis India Limited, has a long corporate history dating back to its incorporation in 1947 as Ciba Pharma Private Limited.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is the total value of Evonile Pharma's proposed rights issue?
Evonile Pharma proposes to raise up to ₹8,847.54 million through its rights issue.
How many shares are being offered in Evonile Pharma's rights issue?
The company is offering 10,287,832 partly paid-up equity shares of face value ₹5 each.
What is the issue price for Evonile Pharma's rights equity shares?
The issue price is ₹860.00 per rights equity share, which includes a premium of ₹855.00.
What is the entitlement ratio for Evonile Pharma's rights issue?
Eligible equity shareholders are entitled to subscribe to 5 rights equity shares for every 12 equity shares held.
What is the record date for Evonile Pharma's rights issue?
The record date for determining eligible shareholders for the rights issue is November 11, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.